Skip to main content
Premium Trial:

Request an Annual Quote

Power3 to Begin Clinical Evaluation of Proteomics-Based Breast Cancer Test

NEW YORK, July 8 (GenomeWeb News) - Power3 Medical Products announced today that clinical evaluation of its proteomics-based early-detection breast cancer test will commence sometime this summer.


According to an outside spokesperson for Power3, the company will begin clinical testing at three undisclosed US sites, and that it would likely be able to announce the exact timing of the trials in a few weeks.


The test uses proteomics techniques such as electrophoresis image analysis and automated mass spectrometry to analyze nipple aspirate, or breast ductal fluid for specific groups of breast cancer proteins. The fluid is collected via a non-invasive modified breast pump procedure.


Power3 said that the test has the potential to detect breast cancer years earlier than current methods. The company also said it has completed proof-of-concept studies and secured the intellectual property for the test.


In May, Power3 acquired proteomics start-up ProteEx, which had been developing the test in collaboration with the M.D. Anderson Cancer Center.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.